Leesburg, VA, July 25, 2018 — Examining the normal distribution, pitfalls, mimics, and imaging characteristics of various tumors using 68Ga DOTATATE PET/CT and the principles and practice of 177Lu DOTATATE therapy will be the focus of an August 20 webinar hosted by the American Roentgen Ray Society (ARRS).
68Ga tetraazacyclododecanetetraacetic acid-DPhe1-Tyr3-octreotate (DOTATATE) PET/CT has become the preferred imaging modality for initial diagnosis, selection of patients for peptide receptor radionuclide therapy, and localization of unknown primary tumors. 177Lu DOTATATE therapy is approved for treatment of patients with GEP NETs which are locally advanced or un-resectable and progressing despite somatostatin analogue therapy.
This ARRS webinar will present a foundational review of 68Ga DOTATATE PET/CT and 177Lu DOTATATE therapy for practicing radiologists, nuclear medicine physicians, nuclear medicine technologists, residents, and patients.
WHO: Rathan Subramaniam, MD, PhD, MPH, AJR Section Editor for Nuclear Medicine and Molecular Imaging; and Erik Mittra, MD, PhD, CCD. WHEN: Wednesday, August 15 at Noon Eastern Time. REGISTRATION: ARRS members as well as non-members may attend this ARRS webinar free of charge. Registration is required at arrs.org/FreeAJRlive. This AJR Live Webinar offers 1 CME Credit. MEDIA REGISTRATION: For accredited media representatives wishing to view the webinar, contact Mike Mason,
Article originally posted at